Key Insights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 4 trials

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed with results

Key Signals

4Total

P 1 (1)

P 2 (3)

Recruiting3

Active Not Recruiting1

Clinical Trials (4)

Showing 4 of 4 trials

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma

RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL

Showing all 4 trials